Results from the CheckMate 214 clinical trial show that combined therapy with two immunotherapy drugs, nivolumab and ipilimumab, can be very effective in the treatment of renal cell carcinoma, the most common type of kidney cancer.
Kidney cancer kills about 14,000 people every year. It is especially deadly when it is found in the late stages. Scott was first diagnosed with kidney cancer in January of 2011 and given only 10 months to live...that was 7 years ago.
Ten years ago, patients diagnosed with advanced-stage kidney cancer had few options, and none of them were very promising. But in recent years, we have seen a revolution in kidney cancer treatment with ten new targeted drugs winning FDA approval.
As Immunotherapy Awareness Month winds down, we want to highlight three different clinical trials being led by physicians at our Center for Immunotherapy of novel immunotherapy approaches for treating genitourinary cancers.
My husband, Brian Townson was in his 60s when he learned that he had collecting duct renal carcinoma (CDC), a rare and very aggressive form of kidney cancer that is usually diagnosed after it has spread to other parts of the body.